The tweet was deleted by the author.
But we saved everything 🙂.
Edgewise Therapeutics reported its financial results for the third quarter of 2026. The stock edges lower on the day, trading at $37.53.
Edgewise Therapeutics announced its financial results for the third quarter of 2026. The announcement also covered recent business highlights from the company. The median price target among analysts is $53, standing about 41.2% above the current trading level.
View post on X Loading...
The session saw an intraday range widen well beyond the weekly average, stretching between $37.41 and $39.28. Price action is developing under a bearish bias, with shares trading below the MA-20 and MA-50 but still above the MA-200, creating a split daily structure. The nearest support remains the weekly low at $36.7. Stoch RSI nearing oversold territory suggests the recent decline may be reaching stretched levels and could limit further short-term downside.
To gauge whether the event is being priced in, traders should watch for a close above $38.73 or a drop below $36.7. During the latest session, shares moved within a wide band, trading between $37.41 and $39.28. Even so, despite a sharp move lower over the past week without a sustained trend, the outlook for the coming trading week carries less than 20% probability of upside and more than 80% of downside, with an expected range from $35.46 to $39.59. A close above $38.73 would indicate buyers are willing to follow through, while a break below $36.7 would suggest the move is being rejected. On the weekly chart the longer-term picture stays constructive.
Previously it was reported that Edgewise Therapeutics maintained a bullish technical outlook, with the longer-term trend viewed as constructive. The current session, however, highlights a shift to a more cautious near-term stance as shares slide below key moving averages, with $36.7 emerging as the critical support level to monitor for confirmation of further downside.